Switzerland’s Relief Therapeutics (RLFTF) Striving To Beat High Records While Developing RLF-100

Not many days left to say “Farewell” to COVID-19 as some biotech firms claim to stop the pandemic next year at all. Meanwhile, Relief Therapeutics (OTC: RLFTF) develops its own candidate RLF-100 to treat COVID-19 patients with critical conditions. That’s why RLFTF shares are on the big spot of visionary investors who are interested in erasing the pandemic.

Although Relief is burning cash crazily as RLF-100 needs a lot of resources and time to be a perfect drug for the coronavirus patients the stockholders are eager to wait for the day when health organizations start ordering the first batch of the drug. Maybe millions of patients will get the cure in February of 2021.

In the OTC market Relief shares rose 2.61% on Friday but in the Swiss exchange, they lost 4.88%. Perhaps, next week they become similar in prices and volumes. The mind-boggling penny RLFTF and RLF.SW shares are still potential opportunities to get wealthy next year. So buying a thousand shares for hundred of dollars may lead you to the next stage of investing experience.

Related:  AstraZeneca (AZN) Continues Rally With Promising Future Amid FDA News

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.